An increasing number of countries are committing to meet the World Health Organization (WHO) targets to eliminate hepatitis C virus (HCV) as a public health threat by 2030. These include service coverage targets (90% diagnosed and 80% of diagnosed patients treated) and impact targets (80% and 65% reductions in incidence and mortality, respectively, compared to 2015 levels). Currently a dozen countries are on track to reach 2030 WHO HCV targets. However, whilst striving for the WHO targets is important, it should be recognized that progress on impact targets are derived from mathematical modelsprojecting decreases in incidence and mortalityon a global scale. Despite HCV treatment access in many counties for a number of years, limited empirical data is available to evaluate progress towards elimination. In some countries, substantial incidence and mortality reductions based on reaching the WHO service coverage targets may be unachievable. For example: in countries with ageing hepatitis C -infected populations, even if they have a quality hepatitis C response, high hepatitis C -related morbidity at baseline may not be reversible even with increased HCV treatment uptake and diagnosis. Finally, WHO targets are not necessarily easily or reliably measurable. Measuring relative impact targets requires high-quality data at baseline (i.e. 2015) and longitudinal data to assess temporal trends. In this commentary we propose alternative additional measures to track progress on reducing the HCV burden,offer examples where the WHO targets may not be informative or achievable, and potential practical solutions.This article is protected by copyright. All rights reserved.
September 24, 2020
[The characteristics of morbidity of population older than able-bodied age in the Russian Federation in 2012-2018].
April 20, 2020
Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute COVID-19 in Pediatric Patients.
August 20, 2020
- CROI 2020Every year, CROI hosts some of the world's leading experts in HIV research, who come to present exciting new data and drive forward the field of HIV/AIDS research. This year, due to COVID-19, CROI held their meeting virtually.